Catalog No. 

CS348066

Species reactivity

Human

Applications 

Research Grade Biosimilar

Host species 

Humanized

Isotype

IgG1-kappa

Expression system 

Mammalian Cells

Clonality 

Monoclonal

Target 

TRAILR2, TRAIL-R2, Death receptor 5, CD262, DR5, Tumor necrosis factor receptor superfamily member 10B, ZTNFR9, TRAIL receptor 2, TRICK2, TNFRSF10B, KILLER, TNF-related apoptosis-inducing ligand receptor 2

Concentration 

1mg/ml

Endotoxin level 

Please contact the lab for this information.

Purity 

>95% purity as determined by SDS-PAGE.

Purification 

Protein A/G, purified from cell culture supernatant.

Accession 

O14763

Form

Liquid

Storage buffer 

0.01M PBS,pH7.4.

Stability and Storage 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -218°C.

Alternate Names 

GEN-1029,HexaBody-DR5/DR5,Hx-DR5-01/05,CAS:2109731-10-2

Background 

Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM).

Note 

For research use only. Not for use in clinical or therapeutic applications.